|
Stereotactic Radiosurgery in Treating Patients With Liver Metastases, Lung Metastases, or Other Advanced Solid Tumors Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for proven healthcare advice, travels to or treatment by using a genuine medical doctor. We are not physicians. Always confer with your doctor on Stereotactic Radiosurgery in Treating Patients With Liver Metastases, Lung Metastases, or Other Advanced Solid Tumors conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Stereotactic Radiosurgery in Treating Patients With Liver Metastases, Lung Metastases, or Other Advanced Solid Tumors Clinical research trials and Stereotactic Radiosurgery in Treating Patients With Liver Metastases, Lung Metastases, or Other Advanced Solid Tumors healthcare trials take place in many of cities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectiveness of new drugs. The function of the studies / undertakings is to answer specific human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector companies to find treatments for all forms of conditions, including Stereotactic Radiosurgery in Treating Patients With Liver Metastases, Lung Metastases, or Other Advanced Solid Tumors. Stereotactic Radiosurgery in Treating Patients With Liver Metastases, Lung Metastases, or Other Advanced Solid Tumors Clinical Trials and other clinical trials allow for volunteers to access medical treatment alternatives before they are available to the masses. Many times the test subjects undergo treatment for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a Stereotactic Radiosurgery in Treating Patients With Liver Metastases, Lung Metastases, or Other Advanced Solid Tumors clinical trial. Test subjects oftentimes recieve the best healthcare possible for their Stereotactic Radiosurgery in Treating Patients With Liver Metastases, Lung Metastases, or Other Advanced Solid Tumors condition. Hazards are a reality, nonetheless, and might include additional or frequent doctor trips, healthcare hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Stereotactic Radiosurgery in Treating Patients With Liver Metastases, Lung Metastases, or Other Advanced Solid Tumors  Stereotactic Radiosurgery in Treating Patients With Liver Metastases, Lung Metastases, or Other Advanced Solid Tumors
Stereotactic Radiosurgery in Treating Patients With Liver Metastases, Lung Metastases, or Other Advanced Solid Tumors
For Condition: unspecified adult solid tumor, protocol specific,lung metastases,liver metastases
Status: No longer recruiting
Sponsor(s): Massey Cancer Center ,
Synopsis: RATIONALE: Stereotactic radiosurgery delivers x-rays directly to the tumor and may cause less damage to normal tissue. PURPOSE: Phase II trial to study the effectiveness of stereotactic radiosurgery in treating patients who have liver metastases, lung metastases, or other advanced solid tumors.
Details: OBJECTIVES: - Determine the feasibility of fractionated stereotactic body radiosurgery in patients with advanced extracranial tumors. - Assess the toxicities of this treatment regimen in these patients. - Determine tumor response and cause of death in these patients treated with this regimen. OUTLINE: Patients receive fractionated stereotactic body radiosurgery over 30 minutes for 5-10 days for a total of 3 treatments. Patients are followed every 3 months. PROJECTED ACCRUAL: A total of 10-25 patients will be accrued within 2-3 years.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically or cytologically confirmed malignancy - Extracranial recurrent or metastatic disease or primary tumor not predicted to be controlled with standard radiotherapy - Incurable with any standard therapy - No tumors involving critical structures (e.g., mucosal surfaces (bowel or bladder) or heart) - Tumor visible by CT scan PATIENT CHARACTERISTICS: Age: - Not specified Performance status: - Karnofsky 60-100% Life expectancy: - Not specified Hematopoietic: - Not specified Hepatic: - Bilirubin less than 2.0 times upper limit of normal (ULN) - AST and ALT less than 5 times ULN Renal: - Creatinine less than 2.0 mg/dL Pulmonary: - FEV1 greater than 0.75 L Other: - No unsuitable size or geometric proportion that would preclude stereotactic immobilization - Not pregnant or nursing - Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: - At least 14 days since prior anticancer biologic therapy and recovered Chemotherapy: - At least 14 days since prior anticancer chemotherapy and recovered Endocrine therapy: - At least 14 days since prior anticancer endocrine therapy and recovered Radiotherapy: - See Disease Characteristics - At least 14 days since prior anticancer radiotherapy and recovered Surgery: - Not specified
Total Enrollment:
Location and Contact Information:
Overall Study Official:
DannySong, Study Chair, Massey Cancer Center
Massey Cancer Center
Richmond, Virginia, 23298-0058
United States
Additional Information:
Study ID Numbers: CDR0000068151; MCV-MCC-9812-2C,NCI-V00-1612
Study Start Date:
Record last reviewed: January 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00006456
Other Unspecified Adult Solid Tumor, Protocol Specific Studies:
1. Sargramostim in Treating Patients With Kidney Cancer That Has Spread to the Lung
2. Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
3. Conventional or Video-Assisted Surgery in Treating Patients With Lung Metastases
4. Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer
5. Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
Related Studies:
Other unspecified adult solid tumor, protocol specific Clinical Trials
Other Virginia Clinical Trials
Other Richmond Clinical Trials
Stereotactic Radiosurgery in Treating Patients With Liver Metastases, Lung Metastases, or Other Advanced Solid Tumors
|
|
|
|
|
|
|
|
